-
-
Overview
-
Minocycline is a broad-spectrum, second-generation tetracycline. Like all tetracyclines, Minocycline shows broad spectrum antibacterial and antiprotozoan activity. It was patented in 1961 (American cyanamid), synthesized in 1966 (Lederle Labs). Formulations containing Minocycline have been used for acne vulgaris, Current research is reviewing its neuroprotective and anti-inflammatory effects. Minocycline has been found to have many non-antibiotic biological effects in experimental models wtih inflammatory basis and autoimmune disorders. It is an indirect inhibitor of inducible nitric oxide synthase. Minocycline is soluble in ethanol, methanol, DMF or DMSO but has limited water solubility.
Please contact us at for specific academic pricing.
Background
Minocycline acts by binding to the 30S and 50S ribosomal sub-units, inhibiting the binding of aminoacyl-tRNA to the ribosomal acceptor (A) site thus blocking protein synthesis. It has many non-antibiotic effects, multiple mechanisms of action have been proposed. A better understanding of the in vivo activity is needed before its therapeutic potential can be accurately assessed.
-
- Properties
- Applications
-
Overview